Short interest for Trevena gives investors a sense of the degree to which investors are betting on the decline of Trevena's stock. Short interest data is updated every two weeks.

Trevena Stock (NASDAQ:TRVN), Short Interest Report

Trevena

Trevena Inc is an American biopharmaceutical company focused on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders.

News

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Movers

Trading Ideas

AGRI

APLM

ATXI

BGLC

BPTH

CAPT

CMND

CNEY

CRKN

CUEN

HKIT

IMPL

Intelligent Bio Solutions Inc. - Common Stock

INBS

MOBQ

MVLA

TIGR

TRVN

Shares of  UP Fintech Holding Limited (NASDAQ: TIGR) surged in pre-market trading after the company results for the third quarter.

Why UP Fintech Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket

ALTO

AMRC

AUGX

AURA

CFIV

CHRS

CLOV

LIFW

NSTG

SNTI

THAR

TMDX

TNON

TRIP

VTYX

Gainers

Senti Biosciences, Inc. (NASDAQ: SNTI) shares surged 120.8% to $0.6450 in pre-market trading after the company reported a new strategic collaboration with Celest Therapeutics for the clinical development of SENTI-301A in China.

Why Alteryx Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket

Biotech

Health Care

Financing

General

Trevena Inc (NASDAQ: TRVN) released preliminary topline data from two Phase 1 proof-of-concept studies of TRV045.

Why Is Neurology Focused Trevena Stock Trading Higher Today?

Trevena Inc

<h3>Gainers</h3>
<ul>
<li>Chromocell Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CHRO#AMEX">CHRO</a>) stock increased by 21.6% to $1.49 during Friday's pre-market session. The company's market cap stands at $8.7 million. </li>
<li>Kineta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KA#NASDAQ">KA</a>) stock moved upwards by 16.62% to $0.57. The market value of their outstanding shares is at $6.2 million. </li>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares moved upwards by 14.83% to $0.28. The company's market cap stands at $5.4 million. </li>
<li>Erasca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERAS#NASDAQ">ERAS</a>) stock rose 13.73% to $2.04. The company's market cap stands at $308.4 million. </li>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIFW#NASDAQ">LIFW</a>) shares moved upwards by 13.25% to $0.94. The company's market cap stands at $14.9 million. As per the press release, Q4 earnings came out 4 days ago. </li>
<li>Cue Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLTH#NASDAQ">HLTH</a>) stock moved upwards by 12.25% to $0.16. The market value of their outstanding shares is at $25.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) stock fell 18.4% to $1.2 during Friday's pre-market session. The company's market cap stands at $8.9 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) stock decreased by 13.31% to $0.36. The market value of their outstanding shares is at $3.3 million. </li>
<li>INVO Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVO#NASDAQ">INVO</a>) stock decreased by 11.85% to $1.34. The company's market cap stands at $3.6 million. As per the news, the Q4 earnings report came out 3 days ago. </li>
<li>Intelligent Bio Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INBS#NASDAQ">INBS</a>) stock fell 10.72% to $2.5. The company's market cap stands at $7.1 million. </li>
<li>Trevena (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) stock decreased by 10.39% to $0.33. The company's market cap stands at $6.0 million. </li>
<li>PaxMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXMD#NASDAQ">PXMD</a>) stock fell 9.58% to $0.69. The market value of their outstanding shares is at $5.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CHRO

ERAS

HLTH

INVO

ISPC

PRTG

PXMD

12 Health Care Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) shares increased by 43.8% to $4.66 during Thursday's pre-market session. The market value of their outstanding shares is at $3.5 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) shares moved upwards by 39.41% to $0.05. The company's market cap stands at $6.3 million. </li>
<li>23andMe Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ME#NASDAQ">ME</a>) stock moved upwards by 26.61% to $0.45. The company's market cap stands at $217.7 million. </li>
<li>Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) shares rose 25.62% to $6.03. The company's market cap stands at $15.6 million. </li>
<li>Trevena (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) stock moved upwards by 22.86% to $0.49. The company's market cap stands at $9.0 million. </li>
<li>Citius Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTXR#NASDAQ">CTXR</a>) stock moved upwards by 16.38% to $0.95. The company's market cap stands at $151.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) shares declined by 22.5% to $3.24 during Thursday's pre-market session. The company's market cap stands at $31.0 million. </li>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) stock decreased by 17.61% to $0.42. The market value of their outstanding shares is at $4.4 million. </li>
<li>Sonoma Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOA#NASDAQ">SNOA</a>) stock declined by 13.75% to $0.14. The company's market cap stands at $2.2 million. </li>
<li>Mustang Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) shares fell 11.12% to $0.34. The company's market cap stands at $3.5 million. </li>
<li>Dynatronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYNT#NASDAQ">DYNT</a>) stock fell 10.26% to $0.53. The market value of their outstanding shares is at $2.5 million. </li>
<li>SeaStar Medical Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICU#NASDAQ">ICU</a>) shares decreased by 9.46% to $0.63. The company's market cap stands at $47.7 million. As per the press release, Q4 earnings came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BNTC

CTXR

DYNT

MBIO

NRXP

SINT

SNGX

SNOA

12 Health Care Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Trevena (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) shares increased by 27.0% to $0.51 during Wednesday's after-market session. The company's market cap stands at $9.2 million. </li>
<li>Mustang Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) stock increased by 11.97% to $0.43. The company's market cap stands at $4.4 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) stock rose 10.32% to $0.04. The market value of their outstanding shares is at $5.0 million. </li>
<li>Fortress Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBIO#NASDAQ">FBIO</a>) stock moved upwards by 6.21% to $1.88. The market value of their outstanding shares is at $36.1 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) stock increased by 5.92% to $1.43. The company's market cap stands at $4.5 million. </li>
<li>Acutus Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFIB#NASDAQ">AFIB</a>) shares moved upwards by 5.51% to $0.17. The company's market cap stands at $5.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) shares decreased by 16.6% to $1.91 during Wednesday's after-market session. The market value of their outstanding shares is at $4.3 million. </li>
<li>DIH Holding US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHAI#NASDAQ">DHAI</a>) stock fell 14.05% to $1.04. The market value of their outstanding shares is at $42.1 million. </li>
<li>Virax Biolabs Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAX#NASDAQ">VRAX</a>) shares fell 8.92% to $0.62. The company's market cap stands at $1.4 million. </li>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) shares declined by 7.85% to $0.47. The market value of their outstanding shares is at $4.9 million. </li>
<li>INVO Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVO#NASDAQ">INVO</a>) shares declined by 7.7% to $1.68. The market value of their outstanding shares is at $4.3 million. As per the press release, Q4 earnings came out yesterday. </li>
<li>ProKidney (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROK#NASDAQ">PROK</a>) shares declined by 6.7% to $2.65. The company's market cap stands at $163.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AFIB

DHAI

FBIO

PROK

TCBP

TCON

VRAX

12 Health Care Stocks Moving In Wednesday's After-Market Session

HC Wainwright &amp; Co. analyst Douglas Tsao maintains Trevena (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) with a Buy and maintains $9 price target.

Price Target

Analyst Ratings

HC Wainwright & Co. Maintains Buy on Trevena, Maintains $9 Price Target

Trevena (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) reported its Q4 earnings results on Monday, April 1, 2024 at 07:00 AM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Trevena missed estimated earnings by -179.0%, reporting an EPS of $-1.06 versus an estimate of $-0.38.
Revenue was down $81 thousand from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company missed on EPS by $0.42 which was followed by a 0.0% increase in the share price the next day.
Here's a look at Trevena's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.15</td>
<td>-1.05</td>
<td>-0.98</td>
<td>-1.75</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.57</td>
<td>-0.69</td>
<td>-0.81</td>
<td>-0.73</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>100K</td>
<td>400K</td>
<td>230K</td>
<td>300K</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>180K</td>
<td>3.02M</td>
<td>6K</td>
<td>0</td>
</tr>
</tbody>
</table>

To track all earnings releases for Trevena <a href="https://www.benzinga.com/quote/TRVN/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Recap: Trevena Q4 Earnings

Trevena (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) reported quarterly losses of $(1.06) per share which missed the analyst consensus estimate of $(0.38) by 178.95 percent. This is a 45.21 percent decrease over losses of $(0.73) per share from the same period last year.

Trevena Q4 EPS $(1.06) Misses $(0.38) Estimate, Cash Balance of $33M

<h3>Gainers</h3>
<ul>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) shares rose 33.9% to $0.83 during Friday's after-market session. The market value of their outstanding shares is at $3.2 million. </li>
<li>Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) shares rose 12.48% to $151.77. The company's market cap stands at $8.0 billion. </li>
<li>Vicarious Surgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBOT#NYSE">RBOT</a>) shares moved upwards by 11.17% to $0.38. The market value of their outstanding shares is at $66.7 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock moved upwards by 11.11% to $2.2. The company's market cap stands at $8.0 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock increased by 9.09% to $1.2. The company's market cap stands at $16.0 million. </li>
<li>Bright Green (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGXX#NASDAQ">BGXX</a>) shares rose 8.02% to $0.29. The company's market cap stands at $53.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NextCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTC#NASDAQ">NXTC</a>) shares declined by 9.5% to $1.72 during Friday's after-market session. The market value of their outstanding shares is at $47.9 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) shares declined by 7.02% to $1.59. The market value of their outstanding shares is at $46.3 million. The company's, Q4 earnings came out yesterday. </li>
<li>Mesoblast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) shares fell 6.49% to $2.02. The company's market cap stands at $204.9 million. </li>
<li>Trevena (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) stock declined by 6.36% to $0.43. The market value of their outstanding shares is at $7.8 million. </li>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) shares decreased by 6.03% to $0.42. The company's market cap stands at $6.7 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Nutriband (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRB#NASDAQ">NTRB</a>) stock fell 5.93% to $2.54. The market value of their outstanding shares is at $21.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BGXX

MASI

MESO

NTRB

NXTC

RBOT

RMTI

SHPH

SLRX

12 Health Care Stocks Moving In Friday's After-Market Session

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Trevena (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) with a Buy and maintains $9 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Trevena, Maintains $9 Price Target

<a href="https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11912693" title="https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11912693">https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11912693</a>

Trevena Granted US Patent 11,912,693 Titled 'Compounds For Modulating S1P1 Activity And Methods Of Using The Same'

https://ppubs.uspto.gov/pubwebapp/external.html?q=(11912713).pn

Trevena Has Been Granted U.S. Patent 11,912,713 Titled "7-membered Aza-Heterocyclic Containing Delta-Opioid Receptor Modulating Compounds, Methods Of Using And Making (For Treating Pain, Migraines, Depression, Parkinsons Disease, And Other Disorders)

<h3>Gainers</h3>
<ul>
<li>Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) shares moved upwards by 8.7% to $0.72 during Tuesday's after-market session. The market value of their outstanding shares is at $23.9 million. </li>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) stock increased by 7.27% to $0.92. The company's market cap stands at $3.0 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) shares rose 7.2% to $2.38. The market value of their outstanding shares is at $1.6 million. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) stock increased by 6.45% to $0.76. The market value of their outstanding shares is at $4.7 million. </li>
<li>Atreca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCEL#NASDAQ">BCEL</a>) stock increased by 6.29% to $0.27. The company's market cap stands at $10.6 million. </li>
<li>ASLAN Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASLN#NASDAQ">ASLN</a>) stock increased by 5.94% to $0.62. The company's market cap stands at $10.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Savara (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRA#NASDAQ">SVRA</a>) stock decreased by 11.9% to $3.75 during Tuesday's after-market session. The company's market cap stands at $507.5 million. </li>
<li>MyMD Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYMD#NASDAQ">MYMD</a>) stock fell 9.22% to $0.18. The company's market cap stands at $9.3 million. </li>
<li>Alector (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALEC#NASDAQ">ALEC</a>) stock fell 8.38% to $7.0. The market value of their outstanding shares is at $588.9 million. </li>
<li>Enliven Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) shares declined by 6.98% to $11.07. The company's market cap stands at $456.2 million. </li>
<li>Estrella Immunopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLA#NASDAQ">ESLA</a>) stock declined by 6.26% to $1.2. The company's market cap stands at $42.2 million. </li>
<li>Trevena (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) stock declined by 4.97% to $0.65. The market value of their outstanding shares is at $11.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALEC

ASLN

BCEL

CNSP

ELVN

ESLA

EVOK

MBRX

MyMD Pharmaceuticals, Inc. - Common Stock

MYMD

SVRA

12 Health Care Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Aura Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AURA#NASDAQ">AURA</a>) stock moved upwards by 44.3% to $13.0 during Tuesday's pre-market session. The company's market cap stands at $640.3 million. </li>
<li>Galera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTX#NASDAQ">GRTX</a>) shares rose 40.01% to $0.21. The company's market cap stands at $11.3 million. </li>
<li>Jin Medical International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJYL#NASDAQ">ZJYL</a>) stock moved upwards by 31.99% to $120.0. The company's market cap stands at $930.0 million. </li>
<li>Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) stock moved upwards by 26.91% to $1.98. The company's market cap stands at $255.9 million. </li>
<li>Lucy Scientific Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSDI#NASDAQ">LSDI</a>) shares moved upwards by 22.83% to $0.24. The company's market cap stands at $4.2 million. </li>
<li>Elicio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELTX#NASDAQ">ELTX</a>) shares increased by 22.37% to $9.57. The market value of their outstanding shares is at $91.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Grifols (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) shares declined by 35.2% to $7.21 during Tuesday's pre-market session. The company's market cap stands at $4.8 billion. </li>
<li>eFFECTOR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFTR#NASDAQ">EFTR</a>) stock fell 19.26% to $0.45. The company's market cap stands at $28.8 million. </li>
<li>Trevena (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) stock decreased by 10.25% to $0.66. The market value of their outstanding shares is at $10.0 million. </li>
<li>Apollomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLM#NASDAQ">APLM</a>) shares fell 10.05% to $0.84. The market value of their outstanding shares is at $74.8 million. </li>
<li>Societal CDMO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCTL#NASDAQ">SCTL</a>) stock decreased by 9.19% to $0.34. The market value of their outstanding shares is at $36.1 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares decreased by 8.47% to $2.92. The company's market cap stands at $2.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CYCC

EFTR

ELTX

GRFS

GRTX

LSDI

MCRB

SCTL

ZJYL

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Trevena Inc. ("Trevena" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has entered into definitive agreements for the issuance and sale of 2,779,906 shares of common stock (or pre-funded warrants in lieu thereof) of Trevena and warrants to purchase up to an aggregate of 2,779,906 shares of common stock of Trevena, at a purchase price of $0.70 per share (or pre-funded warrant in lieu thereof) and associated warrant in a private placement, for expected gross proceeds to the Company of approximately $1.946 million (the "private placement"). &nbsp;
The Company has also entered into a definitive agreement for the immediate exercise for cash of certain existing warrants to purchase up to an aggregate of 2,934,380 shares of common stock issued in July 2022 and November 2022 at a reduced exercise price of $0.70 per share, in exchange for the issuance of unregistered new warrants to purchase up to 5,868,760 shares of common stock, for expected gross proceeds to the Company of approximately $2.054 million (the "induced warrant exercise" and, collectively with the private placement, the "offerings"). The shares of common stock issuable upon exercise of the existing warrants are registered pursuant to an effective registration statement on Form S-3 (File No. 333-251006), filed with the U.S. Securities Exchange ("SEC") on November 27, 2020 and declared effective on December 4, 2020.
The warrants to be issued in the offerings will have an exercise price of $0.70 per share, will be exercisable commencing on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of such warrants and will expire five years thereafter.
H.C. Wainwright &amp; Co. is acting as the exclusive placement agent for the offerings.

Offerings

Trevena Inc. Announces $4M Concurrent Private Placement Of 2,779,906 Shares Of Common Stock At A Price Of $0.70/Share And Warrant Exercise

PINC

Trevena Has Been Awarded A National Group Purchasing Agreement For Olinvyk With Premier Effective December 1, 2023, The New Agreement Allows Premier Members, To Take Advantage Of Special Pricing And Terms Pre-negotiated By Premier For Olinvyk

Shares of UP Fintech Holding Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tigr#NASDAQ">TIGR</a>) surged in pre-market trading after the company results for the third quarter.
UP Fintech Holding posted adjusted EPADS of 10 cents up from 4 cents in the year-ago period. The company&rsquo;s quarterly sales came in at $70.10 million versus, $55.41 million a year earlier.
UP Fintech shares rose 7% to $5.20 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3>Gainers</h3>
<ul>
<li>Mobiquity Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mobq#NASDAQ">MOBQ</a>) shares rose 27.3% to $0.5728 in pre-market trading after gaining around 7% on Friday.</li>
<li>Apollomics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aplm#NASDAQ">APLM</a>) shares rose 26.8% to $1.26 in pre-market trading after surging 14% on Friday. The company&rsquo;s partner in China, Avistone Biotechnology Co. Ltd., recently received conditional approval from the National Medical Products Administration (NMPA) of China for the commercialization of vebreltinib to treat patients with MET exon 14 skipping non-small cell lung cancer (NSCLC).</li>
<li>Crown ElectroKinetics Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crkn#NASDAQ">CRKN</a>) rose 26.6% to $0.2243 in pre-market trading after gaining 4% on Friday.</li>
<li>FLJ Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/flj#NASDAQ">FLJ</a>) shares surged 25.6% to $0.1941 in pre-market trading. FLJ Group shares jumped 45% on Friday after the company announced it entered into a definitive agreement to acquire Alpha Mind Technology.</li>
<li>Avenue Therapeutics, Inc.(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atxi#NASDAQ">ATXI</a>) gained 19.2% to $0.2240 in pre-market trading. Avenue Therapeutics recently posted a profit for the third quarter.</li>
<li>Cyngn Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cyn#NASDAQ">CYN</a>) gained 13.1% to $0.2712 in pre-market trading after gaining 4% on Friday.</li>
<li>CN Energy Group. Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cney#NASDAQ">CNEY</a>) shares rose 12.5% to $0.1170 in pre-market trading after gaining more than 6% on Friday.</li>
<li>Bio-Path Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bpth#NASDAQ">BPTH</a>) shares climbed 11.1% to $0.5364 in pre-market trading. Bio-Path Holdings recently posted a narrower-than-expected quarterly loss.</li>
<li>Captivision Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/capt#NASDAQ">CAPT</a>) rose 10.6% to $2.59 in pre-market trading after surging 44% on Friday.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Impel Pharmaceuticals Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/impl#NASDAQ">IMPL</a>) dipped 22.7% to $0.6532 in pre-market trading after gaining 8% on Friday. Impel Pharmaceuticals recently announced exploration of strategic alternatives.</li>
<li>AgriFORCE Growing Systems Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agri#NASDAQ">AGRI</a>) shares fell 17.5% to $0.80 in pre-market trading.</li>
<li>Movella Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mvla#NASDAQ">MVLA</a>) fell 12.5% to $0.35 in pre-market.</li>
<li>Cuentas Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cuen#NASDAQ">CUEN</a>) shares fell 11.5% to $1.08 in pre-market trading after declining around 12% on Friday.</li>
<li>Trevena, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trvn#NASDAQ">TRVN</a>) shares fell 10.1% to $0.5217 in pre-market trading. Trevena recently posted a third-quarter loss of 57 cents per share.</li>
<li>BioNexus Gene Lab Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bglc#NASDAQ">BGLC</a>) fell 10.1% to $0.8089 in pre-market trading after jumping 144% on Friday.</li>
<li>Hitek Global Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hkit#NASDAQ">HKIT</a>) fell 9.4% to $1.25 in pre-market trading after jumping over 8% on Friday.</li>
<li>Intelligent Bio Solutions Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/inbs#NASDAQ">INBS</a>) shares fell 8.6% to $0.2650 in pre-market trading. The company recently reported first-quarter financial results.</li>
<li>Clearmind Medicine Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cmnd#NASDAQ">CMND</a>) shares fell 7.5% to $0.1106 in pre-market trading. Clearmind Medicine recently announced a 1-for-30 reverse share split.</li>
<li>Pagaya Technologies Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pgy#NASDAQ">PGY</a>) fell 5.8% to $1.29 in pre-market trading after the company said Michael Kurlander, Chief Financial Officer, has stepped down from his role to pursue an outside opportunity. The company named Deputy Chief Financial Officer Evangelos Perros as Interim Chief Financial Officer.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/23/11/35938606/top-5-tech-and-telecom-stocks-that-could-blast-off-in-q4"> Top 5 Tech And Telecom Stocks That Could Blast Off In Q4</a>

Trevena (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) reported its Q3 earnings results on Tuesday, November 14, 2023 at 07:00 AM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Trevena missed estimated earnings by 280.0%, reporting an EPS of $-0.57 versus an estimate of $-0.15.
Revenue was up $618 thousand from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.36 which was followed by a 2.63% drop in the share price the next day.
Here's a look at Trevena's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
<th>Q3 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.05</td>
<td>-0.98</td>
<td>-1.75</td>
<td>-2</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.69</td>
<td>-0.81</td>
<td>-0.73</td>
<td>-2.25</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>400K</td>
<td>230K</td>
<td>300K</td>
<td>440K</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>3.02M</td>
<td>6K</td>
<td>0</td>
<td>-438K</td>
</tr>
</tbody>
</table>

To track all earnings releases for Trevena <a href="https://www.benzinga.com/quote/TRVN/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: Trevena Q3 Earnings

Trevena (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.15) by 280 percent. This is a 74.55 percent increase over losses of $(2.24) per share from the same period last year. The company reported quarterly sales of $180.00 thousand which beat the analyst consensus estimate of $100.00 thousand by 80.00 percent. This is a 141.10 percent increase over sales of $(438.00 thousand) the same period last year.

Trevena Q3 EPS $(0.57) Misses $(0.15) Estimate, Sales $180.00K Beat $100.00K Estimate; Cash And Cash Equivalents Of $35M Is Expected To Be Sufficient To Fund The Company's Operating Expenses And Capital Expenditure Requirements Into Q3 2024

Trevena (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) is set to give its latest quarterly earnings report on Tuesday, 2023-11-14. Here's what investors need to know before the announcement.
Analysts estimate that Trevena will report an earnings per share (EPS) of $-0.15. 
Trevena bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.36, which was followed by a 2.63% drop in the share price the next day.
Here's a look at Trevena's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
<th>Q3 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.05</td>
<td>-0.98</td>
<td>-1.75</td>
<td>-2</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.69</td>
<td>-0.81</td>
<td>-0.73</td>
<td>-2.25</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.63%</td>
<td>6.36%</td>
<td>0.0%</td>
<td>-19.08%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2023/1699894937_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Trevena were trading at $0.57 as of November 10. Over the last 52-week period, shares are down 83.53%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/TRVN/earnings">To track all earnings releases for Trevena visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview: Trevena

Gainers
Senti Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snti#NASDAQ">SNTI</a>) shares surged 120.8% to $0.6450 in pre-market trading after the company reported a new strategic collaboration with Celest Therapeutics for the clinical development of SENTI-301A in China.
Tharimmune, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/thar#NASDAQ">THAR</a>) shares rose 76.8% to $0.2790 in pre-market trading as the company disclosed the execution of an exclusive worldwide licensing agreement with Avior Inc. d/b/a Avior Bio, LLC to develop, market and commercialize a clinical-stage asset, AV104.
TransMedics Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>) shares rose 39.7% to $56.16 in pre-market trading after the company reported better-than-expected third-quarter sales results and issued strong FY23 revenue guidance.
GSE Systems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gvp#NASDAQ">GVP</a>) rose 18.3% to $3.88 in pre-market trading. GSE Solutions was recently awarded a $4.2 million contract from a large utility for nuclear power plant engineering work.
Unisys Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uis#NYSE">UIS</a>) shares climbed 17.7% to $3.40 in pre-market trading after the company posted upbeat third-quarter results and raised the FY23 revenue growth forecast.
Alteryx, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ayx#NYSE">AYX</a>) shares jumped 16.3% to $35.28 in pre-market trading after reporting better-than-expected third-quarter financial results.
Augmedix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/augx#NASDAQ">AUGX</a>) shares rose 15% to $5.23 in pre-market trading following strong third-quarter results.
Color Star Technology Co., Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/add#NASDAQ">ADD</a>) rose 14.9% to $0.3802 in pre-market trading after gaining around 44% on Monday.
CF Acquisition Corp. IV (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cfiv#NASDAQ">CFIV</a>) gained 11.2% to $11.89 in pre-market trading.
Tripadvisor, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trip#NASDAQ">TRIP</a>) shares rose 11% to $17.88 in pre-market trading after the company reported better-than-expected third-quarter financial results.
Losers
Ventyx Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtyx#NASDAQ">VTYX</a>) dipped 74% to $3.66 in pre-market trading after the company announced efficacy results from the Phase 2 trial of VTX958 in plaque psoriasis did not meet the internal target to support further development of VTX958 in psoriasis.
Alto Ingredients, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alto#NASDAQ">ALTO</a>) shares fell 52.4% to $2.34 in pre-market trading after the company reported mixed third-quarter financial results.
MSP Recovery, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lifw#NASDAQ">LIFW</a>) shares fell 24.4% to $7.30 in pre-market trading after jumping 252% on Monday.
Coherus BioSciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/chrs#NASDAQ">CHRS</a>) shares fell 18.9% to $2.87 in pre-market trading after the company reported mixed third-quarter financial results.
Ameresco, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amrc#NASDAQ">AMRC</a>) shares fell 18.4% to $21.70 in pre-market trading following downbeat third-quarter results.
Aura Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aura#NASDAQ">AURA</a>) fell 15.5% to $9.30 in pre-market. Aura Biosciences priced its public offering of 11 million common shares at $9 per share.
Clover Health Investments, Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clov#NASDAQ">CLOV</a>) shares fell 15.1% to $0.96 in pre-market trading following weak quarterly sales.
Trevena, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trvn#NASDAQ">TRVN</a>) shares fell 11.2% to $0.5139 in pre-market trading.
Tenon Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tnon#NASDAQ">TNON</a>) fell 11% to $1.78 in pre-market trading after jumping 57% on Monday. Tenon Medical recently announced it passed an FDA Level 2 Inspection.
NanoString Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nstg#NASDAQ">NSTG</a>) fell 9.4% to $1.25 in pre-market trading after the company posted third-quarter results and narrowed its FY23 revenue guidance.
Now Read This: <a href="https://www.benzinga.com/news/23/11/35617627/amazon-walmart-and-2-other-stocks-insiders-are-selling"> Amazon, Walmart And 2 Other Stocks Insiders Are Selling</a>

<h3>Gainers</h3>
<ul>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) stock increased by 139.8% to $0.7 during Tuesday's pre-market session. The market value of their outstanding shares is at $31.1 million. </li>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) stock increased by 78.18% to $0.28. The market value of their outstanding shares is at $4.9 million. </li>
<li>TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) shares moved upwards by 43.59% to $57.71. The company's market cap stands at $1.8 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Synlogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYBX#NASDAQ">SYBX</a>) shares moved upwards by 19.15% to $2.55. The company's market cap stands at $21.6 million. </li>
<li>Advanced Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHI#NASDAQ">AHI</a>) shares increased by 17.97% to $2.1. The market value of their outstanding shares is at $16.3 million. </li>
<li>Augmedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUGX#NASDAQ">AUGX</a>) stock moved upwards by 17.8% to $5.36. The market value of their outstanding shares is at $218.6 million. The company's, Q3 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Ventyx Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTYX#NASDAQ">VTYX</a>) shares fell 76.2% to $3.35 during Tuesday's pre-market session. The market value of their outstanding shares is at $197.2 million. </li>
<li>Aura Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AURA#NASDAQ">AURA</a>) shares declined by 23.55% to $8.41. The company's market cap stands at $321.2 million. </li>
<li>Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) stock decreased by 22.6% to $2.74. The market value of their outstanding shares is at $291.5 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIFW#NASDAQ">LIFW</a>) stock fell 11.82% to $8.51. The market value of their outstanding shares is at $114.0 million. </li>
<li>Clover Health Investments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) shares declined by 11.51% to $1.0. The company's market cap stands at $484.8 million. The company's, Q3 earnings came out yesterday. </li>
<li>Trevena (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) shares decreased by 11.25% to $0.51. The market value of their outstanding shares is at $7.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SYBX

Trevena, Inc. (TRVN) Q3 2023 Earnings Call Transcript

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Trevena (TRVN – Research Report) and Immunic (IMUX –...

Analysts Offer Insights on Healthcare Companies: Trevena (TRVN) and Immunic (IMUX)

Trevena files for $200M mixed shelf

Trevena announces private placement and warrant exercise

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out on Tuesday to catch up on all of the hottest stock market news for this morning!



Moving stocks this morning are clinical trial data, an acquisition deal and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Sentage (NASDAQ:<a href="https://investorplace.com/stock-quotes/sntg-stock-quote/">SNTG</a>) stock is rocketing more than 57% alongside heavy pre-market trading.</li>



<li>Elicio Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/eltx-stock-quote/">ELTX</a>) shares are soaring over 34% alongside <a href="https://www.nasdaq.com/press-release/nature-medicine-publishes-updated-preliminary-phase-1-data-from-elicio-therapeutics">preliminary Phase 1 clinical trial data</a>.</li>



<li>Syra Health (NASDAQ:<a href="https://investorplace.com/stock-quotes/syra-stock-quote/">SYRA</a>) stock is surging close to 34% with strong early morning trading.</li>



<li>Jin Medical International (NASDAQ:<a href="https://investorplace.com/stock-quotes/zjyl-stock-quote/">ZJYL</a>) shares are increasing 32% without any clear news this morning.</li>



<li>Galera Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/grtx-stock-quote/">GRTX</a>) stock is gaining more than 26% as it sees heavy trading before the opening bell.</li>



<li>Juniper Networks (NYSE:<a href="https://investorplace.com/stock-quotes/jnpr-stock-quote/">JNPR</a>) shares are climbing over 23% alongside <a href="https://www.reuters.com/markets/deals/hewlett-packard-enterprise-nears-13-bln-deal-buy-juniper-networks-wsj-2024-01-08/">reports of a $13 billion deal</a>.</li>



<li>AIM ImmunoTech (NYSEMKT:<a href="https://investorplace.com/stock-quotes/aim-stock-quote/">AIM</a>) stock is heading more than 20% higher on Tuesday morning.</li>



<li>Notable Labs (NASDAQ:<a href="https://investorplace.com/stock-quotes/ntbl-stock-quote/">NTBL</a>) shares are getting an over 18% boost after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317974751&amp;type=PDF&amp;symbol=NTBL&amp;cdn=5b4109cc4075a476a2eae1c7f7386014&amp;companyName=Notable+Labs+Ltd.&amp;formType=RW&amp;formDescription=Registration+Withdrawal+Request&amp;dateFiled=2024-01-08">withdrawing a registration statement</a>.</li>



<li>Wearable Devices (NASDAQ:<a href="https://investorplace.com/stock-quotes/wlds-stock-quote/">WLDS</a>) stock is jumping more than 12% on Monday.</li>



<li>MGO Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/mgol-stock-quote/">MGOL</a>) shares are up over 12% today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Grifols (NASDAQ:<a href="https://investorplace.com/stock-quotes/grfs-stock-quote/">GRFS</a>) stock is plummeting nearly 32% following <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/short-seller-gotham-city-questions-grifols-debt-ratios-2024-01-09/">criticism from a hedge fund</a>.</li>



<li>Cue Health (NASDAQ:<a href="https://investorplace.com/stock-quotes/hlth-stock-quote/">HLTH</a>) shares are diving almost 17% this morning.</li>



<li>Mountain Crest Acquisition (NASDAQ:<a href="https://investorplace.com/stock-quotes/mcag-stock-quote/">MCAG</a>) stock is tumbling more than 15% on Monday.</li>



<li>Cyclacel Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/cycc-stock-quote/">CYCC</a>) shares are taking an over 14% beating after <a href="https://www.nasdaq.com/press-release/cyclacel-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-requirement">rallying yesterday on regained compliance</a>.</li>



<li>Canoo (NASDAQ:<a href="https://investorplace.com/stock-quotes/goev-stock-quote/">GOEV</a>) stock is sliding more than 11% after <a href="https://investorplace.com/2024/01/why-is-canoo-goev-stock-up-12-today/">increasing on Monday</a>.</li>



<li>Hewlett Packard (NYSE:<a href="https://investorplace.com/stock-quotes/hpe-stock-quote/">HPE</a>) shares are decreasing over 10% on <a href="https://finance.yahoo.com/news/juniper-jumps-reports-hewlett-packard-120341284.html">reports it will acquire Juniper Networks</a>.</li>



<li>Trevena (NASDAQ:<a href="https://investorplace.com/stock-quotes/trvn-stock-quote/">TRVN</a>) stock is dropping more than 10% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317973131&amp;type=PDF&amp;symbol=TRVN&amp;cdn=0605e570da8e1e866765848c4e3e53d0&amp;companyName=Trevena+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-01-08">providing a new presentation</a>.</li>



<li>LeddarTech (NASDAQ:<a href="https://investorplace.com/stock-quotes/ldtc-stock-quote/">LDTC</a>) shares are declining over 10% on Tuesday.</li>



<li>Soligenix (NASDAQ:<a href="https://investorplace.com/stock-quotes/sngx-stock-quote/">SNGX</a>) stock is dipping more than 9% after rallying yesterday on <a href="https://www.marketwatch.com/story/soligenix-shares-rise-8-after-sgx945-gets-fda-fast-track-designation-3839cb5b">fast-track designation</a>.</li>



<li>Spectaire (NASDAQ:<a href="https://investorplace.com/stock-quotes/spec-stock-quote/">SPEC</a>) shares close out our pre-market stock movers down over 9%.</li>
</ol>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT771243">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/01/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-jan-9th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Trevena files to sell 2.78M shares for holders

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Trevena (TRVN – Research Report), MoonLake Immunothe...

Analysts Offer Insights on Healthcare Companies: Trevena (TRVN), MoonLake Immunotherapeutics (MLTX) and Senseonics Holdings (SENS)

Trevena Inc (TRVN) has issued an announcement. Discover the latest insights into our business strategies and performance with the newly updated cor...

Trevena Inc Unveils Updated Corporate Strategy Presentation

Analyst Jason Butler of JMP Securities reiterated a Buy rating on Trevena (TRVN – Research Report), with a price target of $3.00. Jason Butler has ...

Buy Rating Affirmed for Trevena Amid Strategic Focus on Promising TRV045 Development

Analyst Douglas Tsao from H.C. Wainwright maintained a Buy rating on Trevena (TRVN – Research Report) and keeping the price target at $9.00. Dougla...

Buy Rating Affirmed on Trevena as Focus Shifts to Promising Drug Candidate TRV045

GOEV

IMUX

JNPR

LDTC

MCAG

MGOL

MLTX

NTBL

SENS

SNTG

SPEC

SYRA

WLDS

Press Releases

Trevena Announces Completion of Initial Analysis of OLINVYK Continuous Respiratory Monitoring Data from VOLITION Study and Presentation at American Society of Anesthesiologists Conference

Trevena Reports Favorable TRV045 Topline Safety and Tolerability Data from Proof-of-Concept Studies

Trevena to Release Third Quarter 2023 Financial Results on November 14, 2023

Trevena Reports Third Quarter 2023 Results and Provides Business Update

Trevena Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn Injuries

Trevena Awarded OLINVYK Agreement with Premier, Inc.

Trevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meeting

Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise

Trevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercise

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Trevena Stock (NASDAQ:TRVN), Short Interest Report

People Also Watch